Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A -Rearranged AML
Cancer Genomics - Proteomics · 2026-11 · 23 (6) · 1145-1157
DOI: 10.21873/cgp.20621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, online erschienen am 31.10.2026. Verfasst von Wonwoo Choi und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Biotechnology, BK21 Plus KNU Creative BioResearch Group, Kyungpook National University, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Protein Kinase Inhibitors. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Biotechnology, BK21 Plus KNU Creative BioResearch Group, Kyungpook National University, Daegu, Republic of Korea.
- School of Life Science and Biotechnology, BK21 Plus KNU Creative BioResearch Group, Kyungpook National University, Daegu, Republic of Korea slee@knu.ac.kr.
Zitieren
APA
Choi, W., & Lee, S. (2026). Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A -Rearranged AML. Cancer Genomics - Proteomics, 23(6), 1145-1157. https://doi.org/10.21873/cgp.20621
Vancouver
Choi W, Lee S. Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A -Rearranged AML. Cancer Genomics - Proteomics. 2026;23(6):1145-1157. doi:10.21873/cgp.20621
BibTeX
@article{Choi2026,
author = {Choi, Wonwoo and Lee, Sanggyu},
title = {Transcriptomic Features Associated With Kinase Inhibitor Sensitivity in KMT2A -Rearranged AML},
journal = {Cancer Genomics - Proteomics},
year = {2026},
volume = {23},
number = {6},
pages = {1145--1157},
doi = {10.21873/cgp.20621}
}
EUVIMED